%PDF-1.4
%
28 0 obj
<>
endobj
25 0 obj
<>
endobj
96 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-08-05T13:26:19Z
2024-03-28T22:00:33-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T22:00:33-07:00
application/pdf
Heather
2005-496.sept
uuid:6d9ba7ce-1dd2-11b2-0a00-1b09271d5700
uuid:6d9ba7d0-1dd2-11b2-0a00-bf0000000000
endstream
endobj
14 0 obj
<>
endobj
15 0 obj
<>
endobj
29 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
110 0 obj
[114 0 R]
endobj
111 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
12 789 587 -785 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
-0.00011 Tc 0.0838 Tw 9.7 0 0 10 53.5 735.3264 Tm
(explored. Data from several studies suggest a role for HLA-)Tj
0 Tc 0.32809 Tw 0 -1.2 TD
[(DRB1 allele, )17.8 (TNF-)]TJ
/T1_0 1 Tf
0 Tw 8.3308 0 Td
(\002)Tj
/TT0 1 Tf
0.328 Tw [0.1 (, and IL-10 promoter polymorphism)]TJ
0.02 Tc 0.4369 Tw -8.3307 -1.2 Td
[(associations with )54.9 (American College of Rheumatology)]TJ
-0.00011 Tc 0.1624 Tw T*
(response criteria in patients with RA)Tj
0.00031 Tc 0 Tw 7.27 0 0 7.5 203.3172 702.6265 Tm
(24-27)Tj
0 Tc 0.16229 Tw 9.7 0 0 10 220.2881 699.3264 Tm
(. Pharmacogenetic)Tj
0.0556 Tw -17.1946 -1.2 Td
(studies are likely to provide clinicians with clues to identify-)Tj
-0.00011 Tc 0.02499 Tw T*
[(ing )54.8 (AS responders to )17.7 (TNF-)]TJ
/T1_0 1 Tf
0 Tc 0 Tw [-0.4 (\002)]TJ
/TT0 1 Tf
-0.00011 Tc 11.8191 0 Td
(blockers.)Tj
0 Tc 0.0564 Tw -10.5795 -1.2 Td
[(W)79.8 (e expect that increasing the number of patients with )54.9 (AS)]TJ
-0.0062 Tw -1.2396 -1.2 Td
[(treated with )17.8 (TNF-)]TJ
/T1_0 1 Tf
-0.00011 Tc 0 Tw 7.1889 0 Td
(\002\001)Tj
/TT0 1 Tf
0 Tc -0.0062 Tw 0.8747 0 Td
(blockers will help identify the factors that)Tj
0.1293 Tw -8.0636 -1.2 Td
[(predict response in patients with )54.8 (AS. Not surprisingly)64.9 (, such)]TJ
0.01241 Tc 0.36259 Tw T*
(factors should be those that clinicians have intuitively)Tj
0 Tc -0.0314 Tw T*
(assumed to be involved in determining which patients respond)Tj
-0.00011 Tc 0.00729 Tw T*
(to TNF-)Tj
/T1_0 1 Tf
0 Tw (\002\001)Tj
/TT0 1 Tf
4.1624 0 Td
(blockers.)Tj
/TT1 1 Tf
-0.0002 Tc 0.02499 Tw -0.9149 -2.4 Td
[(RUB\311N BURGOS-V)128.7 (ARGAS,)]TJ
/TT0 1 Tf
0 Tw 5.82 0 0 6 210.5905 579.3264 Tm
(MD,)Tj
0 Tc 0.02499 Tw 7.76 0 0 8 85 569.3264 Tm
(Rheumatology Department,)Tj
0 -1.25 TD
(Hospital General de M\351xico,)Tj
T*
[(Universidad Nacional )54.9 (Aut\363noma de M\351xico, Faculty of Medicine;)]TJ
/TT1 1 Tf
-0.00011 Tc 9.7 0 0 10 85 537.3264 Tm
(JORGE ROJAS-SERRANO,)Tj
/TT0 1 Tf
-0.0002 Tc 0 Tw 5.82 0 0 6 208.6107 537.3264 Tm
(MD,)Tj
0 Tc 0.02499 Tw 7.76 0 0 8 85 527.3264 Tm
[(Rheumatologist and Research Fellow)64.9 (,)]TJ
T*
(Hospital General de M\351xico,)Tj
T*
[(Universidad Nacional )54.9 (Aut\363noma de M\351xico, Faculty of Medicine,)]TJ
T*
[(Mexico City)64.9 (, Mexico.)]TJ
/TT2 1 Tf
-0.00011 Tc -4.0593 -2.75 Td
[(Addr)36.8 (ess r)36.8 (eprint r)36.8 (equests to Pr)36.8 (of. R. Bur)36.8 (gos-V)110.7 (ar)36.8 (gas, Rheumatology)]TJ
T*
(Department, Hospital General de M\351xico, Dr Balmis 148, M\351xico DF)Tj
0 Tc T*
[(06726, M\351xico. E-mail: bur)36.9 (gosv@attglobal.net)]TJ
/TT1 1 Tf
-0.00011 Tc 0 Tw 9.7 0 0 10 53.5 431.3264 Tm
(REFERENCES)Tj
/TT0 1 Tf
0.02499 Tw 8 0 0 8 60.5 421.3264 Tm
[(1.)-875.1 (Davis JC, van der Heijde D, Dougados M, et al. Baseline factors)]TJ
1.675 -1.25 Td
[(that influence )54.8 (ASAS 20 response in patients with ankylosing)]TJ
0 Tc T*
(spondylitis treated with etanercept. J Rheumatol 2005;32:1751-4.)Tj
-0.00011 Tc -1.675 -1.2875 Td
[(2.)-875.1 (Braun J, Pham )17.7 (T)73.9 (,)-0.1 ( Sieper J, et al, and the )54.8 (ASAS )17.7 (W)79.7 (orking Group.)]TJ
1.675 -1.2875 Td
[(International )54.8 (ASAS consensus statement for the use of anti-tumour)]TJ
0 Tc 0 -1.2875 TD
[(necrosis factor agents in patients with ankylosing spondylitis. )54.9 (Ann)]TJ
T*
(Rheum Dis 2003;62:817-24.)Tj
-0.00011 Tc -1.675 -1.2875 Td
[(3.)-875.1 (Maksymowych )17.7 (WC, Inman RD, Gladman D, )17.7 (Thomson G, Stone M,)]TJ
1.675 -1.2875 Td
[(Karsh J, Russell )54.8 (AS, the Spondyloarthritis Research Consortium of)]TJ
0 Tc T*
[(Canada \(SP)91.8 (ARCC\). Canadian Rheumatology )54.8 (Association)]TJ
-0.00011 Tc T*
(Consensus for the use of anti-tumor necrosis factor directed)Tj
0 Tc T*
(therapies in the treatment of the spondyloarthritis. J Rheumatol)Tj
0 Tw T*
(2003;30:1356-63.)Tj
0.0249 Tw -1.675 -1.2875 Td
[(4.)-875 (Keat )54.8 (A, Barkham N, Bhalla )54.8 (A, et al. BSR guidelines for prescribing)]TJ
1.675 -1.2875 Td
(TNF-alpha blockers in adults with ankylosing spondylitis. Report)Tj
T*
[(of a working party of the British Society for Rheumatology)64.9 (.)]TJ
T*
(Rheumatology Oxford 2005;44:939-47.)Tj
-0.00011 Tc -1.675 -1.2875 Td
[(5.)-875.1 (Pham )17.7 (T)73.9 (, Landewe R, Dougados M, et al. ISASS: International Start)]TJ
1.675 -1.2875 Td
[(TNF-Blocker Study in )54.8 (Ankylosing Spondylitis [abstract]. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 2004;50 Suppl:S216.)Tj
-1.675 -1.2375 Td
[(6.)-875 (Landewe R, Rump B, van der Heijde D, van der Linden S. )17.8 (Which)]TJ
1.675 -1.2375 Td
(patients with ankylosing spondylitis should be treated with tumour)Tj
0 -1.2375 TD
[(necrosis factor inhibiting therapy? )54.9 (A)-219.8 (survey among Dutch)]TJ
T*
[(rheumatologists. )54.9 (Ann Rheum Dis 2004;63:530-4.)]TJ
-0.00011 Tc -1.675 -1.2375 Td
[(7.)-875.1 (Garrett S, Jenkinson )17.7 (T)73.9 (,)-0.1 ( Kennedy LG, )17.7 (Whitelock H, Gaisford P)110.7 (,)]TJ
0 Tc 1.675 -1.2375 Td
[(Calin )54.9 (A. )54.9 (A)-219.8 (new approach to defining disease status in ankylosing)]TJ
-0.00011 Tc T*
[(spondylitis: )17.7 (The Bath )54.8 (Ankylosing Spondylitis Disease )54.8 (Activity)]TJ
T*
(Index \(BASDAI\). J Rheumatol 1994;21:2286-91.)Tj
-1.675 -1.2375 Td
[(8.)-875.1 (Anderson JJ, Baron G, van der Heijde D, Felson DT)73.9 (, Dougados M.)]TJ
0 Tc 1.675 -1.2375 Td
(Ankylosing spondylitis assessment group preliminary definition of)Tj
T*
[(short-term improvement in ankylosing spondylitis. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
(2001;44:1876-86.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.225 Td
[(9.)-875.1 (Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a)]TJ
34.675 79.8834 Td
(major clinical response \(BASDAI 50\) to tumour necrosis factor)Tj
0 Tc 0 -1.225 TD
[(alpha blockers in ankylosing spondylitis. )54.8 (Ann Rheum Dis)]TJ
0 Tw T*
(2004;63:665-70.)Tj
0.0249 Tw -2.175 -1.225 Td
[(10.)-875 (van )17.7 (T)34.9 (uber)17.8 (gen )54.8 (A, van der Heijde D, )54.8 (Anderson J, et al. Comparison)]TJ
-0.00011 Tc 2.175 -1.225 Td
[(of statistically derived )54.8 (ASAS improvement criteria for ankylosing)]TJ
0 Tc T*
(spondylitis with clinically relevant improvement according to an)Tj
T*
[(expert panel. )54.9 (Ann Rheum Dis 2003;62:215-21.)]TJ
-0.00011 Tc -2.1381 -1.225 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Stone MA, Inman RD, )17.7 (W)39.7 (right JG, Maetzel )54.8 (A. )17.7 (V)111 (alidation exercise)]TJ
0 Tc 2.1381 -1.225 Td
[(of the )54.8 (Ankylosing Spondylitis )54.8 (Assessment Study \(ASAS\) group)]TJ
T*
(response criteria in ankylosing spondylitis patients treated with)Tj
T*
[(biologics. )54.9 (Arthritis Rheum 2004;51:316-20.)]TJ
-2.175 -1.225 Td
[(12.)-875 (Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun)]TJ
2.175 -1.225 Td
(J. Development and preselection of criteria for short term)Tj
T*
(improvement after anti-TNF alpha treatment in ankylosing)Tj
T*
[(spondylitis. )54.9 (Ann Rheum Dis 2004;63:1438-44.)]TJ
-2.175 -1.225 Td
[(13.)-875 (Braun J, Brandt J, Listing J, et al. )17.8 (T)69.8 (wo year maintenance of ef)17.8 (ficacy)]TJ
2.175 -1.225 Td
(and safety of infliximab in the treatment of ankylosing spondylitis.)Tj
T*
(Ann Rheum Dis 2005;64:229-34.)Tj
-2.175 -1.225 Td
[(14.)-875 (Braun J, Brandt J, Listing J, et al. )17.8 (T)34.9 (reatment of active ankylosing)]TJ
2.175 -1.225 Td
(spondylitis with infliximab: a randomised controlled multicentre)Tj
T*
[(trial. Lancet 2002;359:1)36.9 (187-93.)]TJ
-0.00011 Tc -2.175 -1.225 Td
[(15.)-875.1 (Brandt J, Khariouzov )54.8 (A, Listing J, et al. Six-month results of a)]TJ
0 Tc 2.175 -1.225 Td
(double-blind, placebo-controlled trial of etanercept treatment in)Tj
T*
[(patients with active ankylosing spondylitis. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
(2003;48:1667-75.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.225 Td
[(16.)-875.1 (Stone MA, Payne U, Pacheco-T)69.7 (ena C, Inman RD. Cytokine)]TJ
0 Tc 2.175 -1.225 Td
(correlates of clinical response patterns to infliximab treatment of)Tj
T*
[(ankylosing spondylitis. )54.9 (Ann Rheum Dis 2004;63:84-7.)]TJ
-0.00011 Tc -2.175 -1.225 Td
[(17.)-875.1 (Creemers MC, Franssen MJ, van \221t Hof MA, Gribnau FW)91.7 (, van de)]TJ
0 Tc 2.175 -1.225 Td
[(Putte LB, van Riel PL. )54.8 (Assessment of outcome in ankylosing)]TJ
T*
[(spondylitis: an extended radiographic scoring system. )54.9 (Ann Rheum)]TJ
T*
(Dis 2005;64:127-9.)Tj
-0.00011 Tc -2.175 -1.225 Td
[(18.)-875.1 (Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J.)]TJ
0 Tc 2.175 -1.225 Td
(Radiographic progression in patients with ankylosing spondylitis)Tj
-0.00011 Tc T*
[(after two years of treatment with the tumor necrosis factor)19.7 (-)]TJ
/T1_0 1 Tf
0 Tc 0 Tw [0.3 (\002)]TJ
/TT0 1 Tf
0.02499 Tw T*
[(antibody infliximab. )54.9 (Ann Rheum Dis 2005 Mar 18; e-pub ahead of)]TJ
0 Tw T*
(print.)Tj
0.0249 Tw -2.175 -1.225 Td
[(19.)-875 (Davis JC Jr)39.8 (, van der Heijde D, Braun J, et al; Enbrel )54.8 (Ankylosing)]TJ
2.175 -1.225 Td
(Spondylitis Study Group. Recombinant human tumor necrosis)Tj
T*
(factor receptor \(etanercept\) for treating ankylosing spondylitis: a)Tj
T*
[(randomized, controlled trial. )54.9 (Arthritis Rheum 2003;48:3230-6.)]TJ
-2.175 -1.225 Td
[(20.)-875 (Liang KY)128.9 (, Zeger JL. Longitudinal data analysis using generalized)]TJ
2.175 -1.225 Td
(linear models. Biometrika 1986;73:12-22.)Tj
-0.00011 Tc -2.175 -1.225 Td
[(21.)-875.1 (Armitage P)110.7 (, Berry G, Matthews JNS. Statistical methods in medical)]TJ
0 Tc 2.175 -1.225 Td
(research. 4th ed. Oxford: Blackwell Scientific; 2002:440-3.)Tj
-0.00011 Tc -2.175 -1.2375 Td
[(22.)-875.1 (Hider SL, Buckley C, Silman )54.8 (AJ, Symmons DP)110.7 (, Bruce IN. Factors)]TJ
0 Tc 2.175 -1.2375 Td
(influencing response to disease modifying antirheumatic drugs in)Tj
0 -1.2375 TD
[(patients with rheumatoid arthritis. J Rheumatol 2005;32:1)36.9 (1-6.)]TJ
-0.00011 Tc -2.175 -1.2375 Td
[(23.)-875.1 (Anderson JJ, )17.7 (W)79.7 (ells G, )17.7 (V)111 (erhoeven )54.8 (AC, Felson DT)73.9 (. Factors)]TJ
0 Tc 2.175 -1.2375 Td
[(predicting response to treatment in rheumatoid arthritis. )17.8 (The)]TJ
T*
[(importance of disease duration. )54.9 (Arthritis Rheum 2000;43:22-9.)]TJ
-2.175 -1.2375 Td
[(24.)-875 (Martinez )54.8 (A, Salido M, Bonilla G, et al. )54.8 (Association of the major)]TJ
2.175 -1.2375 Td
(histocompatibility complex with response to infliximab therapy in)Tj
T*
[(rheumatoid arthritis patients. )54.9 (Arthritis Rheum 2004;50:1077-82.)]TJ
-0.00011 Tc -2.175 -1.2375 Td
[(25.)-875.1 (Criswell LA, Lum RF)79.7 (, )17.7 (T)34.8 (urner KN, et al. )17.7 (The influence of genetic)]TJ
0 Tc 2.175 -1.2375 Td
[(variation in the HLA-DRB1 and L)91.8 (T)79.8 (A-TNF regions on the response)]TJ
T*
(to treatment of early rheumatoid arthritis with methotrexate or)Tj
T*
[(etanercept. )54.9 (Arthritis Rheum 2004;50:2750-6.)]TJ
-2.175 -1.2375 Td
[(26.)-875 (Kang CP)110.8 (, Lee KW)91.8 (, )36.8 (Y)100.1 (oo DH, Kang C, Bae SC. )17.7 (The influence of a)]TJ
2.175 -1.2375 Td
(polymorphism at position \226857 of the tumour necrosis factor alpha)Tj
T*
(gene on clinical response to etanercept therapy in rheumatoid)Tj
T*
(arthritis. Rheumatology Oxford 2005;44:547-52.)Tj
-2.175 -1.225 Td
[(27.)-875 (Schotte H, Schluter B, Drynda S, et al. Interleukin 10 promoter)]TJ
2.175 -1.225 Td
(microsatellite polymorphisms are associated with response to long)Tj
0 -1.225 TD
(term treatment with etanercept in patients with rheumatoid arthritis.)Tj
T*
(Ann Rheum Dis 2005;64:575-81.)Tj
ET
/CS0 CS 0 0 0 1 SCN
53.46 77 m
558.47 77 l
S
0 0 0 0 scn
52.32 70.16 64.18 -15.66 re
f*
BT
0 0 0 1 scn
/TT2 1 Tf
0 Tw 8 0 0 8 53.3216 57.2343 Tm
(1640)Tj
ET
0 0 0 0 scn
355.5 70.16 203 -15.66 re
f*
BT
0 0 0 1 scn
/TT2 1 Tf
0.02499 Tw 8 0 0 8 423.8613 57.2343 Tm
(The Journal of Rheumatology 2004; 31:9)Tj
ET
0 0 0 0 scn
/GS0 gs
104.09 82.08 407.5 -10.83 re
f*
0.5 w
104.09 82.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_1 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_2 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
34 0 obj
<>
endobj
87 0 obj
<>
endobj
101 0 obj
<>
endobj
39 0 obj
<>
endobj
48 0 obj
<>
endobj
32 0 obj
<>
endobj
33 0 obj
<>
endobj
67 0 obj
<>stream
HVpTι&B $pDL7dW@`<`$@&HaȠU`jHRIF0e)DA{MxL9|{B (ȝBf_:_0CtbQyԅ@@|XTU_K׀6bv3#Pٯ,.g\`d$PƛJeD|@{W.
ʼ e4_*,̖o/^5P^*xX
gPżMjPW,(לLRgVI塳RD"6֍P$mPw7Є^HC& !+hw ؆2]
X8ʋQET_XAx ш8<
I{8.v@MZpc8#7L('G|id^NcFܩQD#ÁhOori)"k:?<w5Vc1CV*
V:fD_c;ǧh1MF[=Vuу>1qc6j3pYDb{8%[YPcm$2O34]p5
xD)lY&gd'TE]^HvJ ϑǺ oٻuD0;s-{BN!zLFd%+ezByC,oͷ>c縗]0{2 [1Ov;$rkN-۸D%b8bEGpj#\1YTF,oZb)>X1'%r\.R"dTǨjԪmcAC3BU#ӊҬ*kjbWW2IgWc"G.OtBJ1Yjg=72ÏQ>Y:NgqPYHO{ө)=_ݓ%vMN1;Doth"2F_7Sjy#@A1)ya3IK-Kfi<10sg^C7dz(zM-ZM
3ȸ\н eٺ)̩*zٌ